Search
Breast Cancer Paid Clinical Trials in Massachusetts
A listing of 161 Breast Cancer clinical trials in Massachusetts actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
121 - 132 of 161
The state of Massachusetts currently has 161 active clinical trials seeking participants for Breast Cancer research studies. These trials are conducted in various cities, including Boston, Worcester, Springfield and Burlington.
Featured Trial
Lung or Breast Cancer Treatment
Recruiting
Diagnosed w/ Lung or Breast Cancer - Underwent Cancer Treatment, Take a step towards hope and healing. Enroll now in our clinical trial for an innovative breast and lung cancer treatment
Conditions:
Cancer
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Clinical Study
Recruiting
We are evaluating an investigational treatment to see if it may help people dealing with chronic cough.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required. If you qualify, you may receive:
Payment up to $1500, which varies by study.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required. If you qualify, you may receive:
Payment up to $1500, which varies by study.
Conditions:
Cough
Chronic Cough
Asthma
Allergic Asthma
Sinusitis
Featured Trial
Healthy Volunteer Trials
Recruiting
Healthy trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Healthy
Featured Trial
Healthy Volunteer Clinical Studies
Recruiting
Find a study looking for volunteers at a study site near you! Some trials offer compensation for time and travel. Click through to learn more about study opportunities.
Conditions:
Healthy
Healthy Volunteers
Featured Trial
Breast Cancer Study
Recruiting
If you have stage 4 breast cancer, you may be able to help advance medical research. Learn about DYNASTY-Breast02 Study enrolling now.
Study to Evaluate CCS1477 in Advanced Tumours
Recruiting
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with metastatic castration resistant prostate cancer, metastatic breast cancer, non-small cell lung cancer or advanced solid tumours.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/18/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Metastatic Castration-Resistant Prostate Cancer, Advanced Solid Tumors, Metastatic Breast Cancer, Non-small Cell Lung Cancer
Losartan in Prevention of Radiation-Induced Heart Failure
Recruiting
This study is being done to see if losartan affects the chances of developing radiation-induced heart failure in patients who are receiving radiation therapy as part of standard of care treatment for breast cancer.
The interventions involved in this study are:
Losartan
Radiation Therapy (standard of care)
Gender:
Female
Ages:
18 years and above
Trial Updated:
01/11/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Ultrahypofractionation and Normal Tissue Toxicity
Recruiting
This research is being done to see if proton beam radiation therapy (PBT) results in fewer changes to a participant's heart measured with MRI-imaging than conventional or "photon" radiation therapy (XRT) for participants with non-metastatic left sided breast cancer.
The names of the two study groups in this research study are:
Proton Radiation Therapy (PBT)
Conventional or "Photon" Radiation Therapy (XRT)
Gender:
Female
Ages:
18 years and above
Trial Updated:
01/11/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Breast Cancer, Breast Cancer Female, Breast Cancer Stage II, Breast Cancer Stage III, Myocardial Fibrosis
Phase 1b Combo w/ Ribociclib and Alpelisib
Recruiting
This is a Phase 1b open-label, 2-part study in 2 treatment groups. The 2 treatment groups are as follows:
Treatment Group 1: OP-1250 in combination with ribociclib (KISQALI®, Novartis Pharmaceuticals Corporation).
Treatment Group 2: OP-1250 in combination with alpelisib (PIQRAY®, Novartis Pharmaceuticals Corporation).
Gender:
All
Ages:
18 years and above
Trial Updated:
01/09/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Metastatic Breast Cancer, Advanced Breast Cancer, HR-positive Breast Cancer, HER2-negative Breast Cancer
Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
Recruiting
This phase III trial compares the effect of adding whole brain radiotherapy with hippocampal avoidance and memantine to stereotactic radiosurgery versus stereotactic radiosurgery alone in treating patients with cancer that has spread to the brain and come back in other areas of the brain after earlier stereotactic radiosurgery. Hippocampus avoidance during whole-brain radiation therapy decreases the amount of radiation that is delivered to the hippocampus, which is a brain structure that is impo... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/09/2024
Locations: Tufts Medical Center, Boston, Massachusetts
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Digestive System Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Brain Neoplasm, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
Recruiting
This is a Phase 1/2, first-in-human, open-label, dose escalation and dose-expansion study of E-602, administered alone and in combination with cemiplimab.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/22/2023
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Oncology, Melanoma, Ovarian Cancer, NSCLC, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Cancer, CRC, Colon Cancer, Breast Cancer, Gastric Cancer, EGJ, Esophagogastric Junction Cancer, Head and Neck Cancer, Urothelial Cancer, Bladder Cancer
A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer
Recruiting
The researcher are doing this study to find out whether benralizumab is effective at preventing skin rashes caused by alpelisib in people who have metastatic breast cancer. Skin rash is a common side effect of alpelisib. Researchers think adding benralizumab to the standard-of-care hormone treatment and alpelisib may prevent the patient from getting a rash.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/21/2023
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Breast Cancer
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Recruiting
The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/20/2023
Locations: Mercy Medical Center, Springfield, Massachusetts
Conditions: Breast Cancer
Refining Local-Regional Therapy for IBC
Recruiting
This Feasibility study is trying to determine:
If Lymphoscintigraphy (imaging of the lymphatic drainage patterns) is effective in demonstrating the drainage to the sentinel lymph nodes in patients with inflammatory breast cancer.
The likelihood of identifying the sentinel lymph nodes in the operating room, using both blue dye and the radioactive substance used for lymphoscintigraphy.
The incidence of lymphedema (arm swelling which occurs after lymph node surgery) in women with inflammatory brea... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
12/18/2023
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
Recruiting
The researchers are doing this study to find out if the study drug, enzalutamide, alone or combined with the study drug, mifepristone, is effective in treating advanced or metastatic androgen receptor-positive (AR+) triple negative breast cancer (TNBC) or estrogen receptor-low breast cancer (ER-low BC), and whether these study treatments work as well as standard chemotherapy with carboplatin, paclitaxel, capecitabine, or eribulin.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/13/2023
Locations: Dana Farber Cancer Institute (Data Collection Only), Boston, Massachusetts
Conditions: Metastatic Breast Cancer
Testing Home-based Exercise Strategies in Underserved Minority Cancer Patients Undergoing Chemotherapy: the THRIVE Study
Recruiting
The purpose of this research is to determine whether a 16 week, home-based, aerobic and resistance exercise intervention will increase physical activity levels in Black and Hispanic breast, colorectal, or prostate cancer patients.
The names of the study interventions involved in this study are:
Supervised aerobic and resistance exercise (SUP) - virtually supervised 16- week aerobic and resistance exercise performed at home via Zoom.
Unsupervised aerobic and resistance exercise (UNSUP) - home-b... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/21/2023
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Video Education With Result Dependent dIsclosure
Recruiting
The overall study objective of this trial study is to identify and evaluate strategies to improve the accessibility of the video education with result dependent disclosure (VERDI) model, increasingly utilized as a pre-genetic testing (pretest) education alternative in clinical practice, to better serve a more diverse patient population at risk for hereditary cancers.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/15/2023
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Genetic Testing, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Colorectal Cancer, Renal Cancer, Melanoma, Sarcoma
121 - 132 of 161